Drug class profile · refreshed daily from federal data

Sulfonylurea

8 molecules in this class, $204.6M combined CY2024 Part D spend across 18.8M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Sulfonylurea class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 8tracked in Part D
CY24 Part D spend: $204.6Mcombined across class
Total Rx claims: 18.8M6.0M unique beneficiaries
Generic mfrs (active): 36across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Glipizide

Brand: Glucotrol · 11.7M Part D claims (CY24) · 3.8M beneficiaries · First FDA approval: 1995-02-27

11 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.035

→

Avg plan cost$0.092

Part D spend $138.2M 3× spread, current vs floor

Class share

68%

of class CY24 spend

View profile →

Glimepiride

6.8M Part D claims (CY24) · 2.2M beneficiaries · First FDA approval: 2005-10-06

8 generic mfrs 3 plans require PA

Low NADAC$0.022

→

Avg plan cost$0.038

Part D spend $62.0M 2× spread, current vs floor

Class share

30%

of class CY24 spend

View profile →

Glyburide

291K Part D claims (CY24) · 103K beneficiaries · First FDA approval: 1984-05-01

7 generic mfrs 219 plans require PA Discontinued

Low NADAC$0.060

→

Avg plan cost$0.075

Part D spend $4.5M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Glipizide and Metformin

— Part D claims (CY24) · First FDA approval: 2005-10-28

4 generic mfrs 0 plans require PA

Low NADAC$0.196

→

Avg plan cost$0.243

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Glipizide-Tablets

Brand: GLIPIZIDE · — Part D claims (CY24) · First FDA approval: 2026-03-04

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Glyburide and Metformin

— Part D claims (CY24) · First FDA approval: 2007-11-14

5 generic mfrs 108 plans require PA

Low NADAC$0.170

→

Avg plan cost$0.177

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Glyburide-Metformin

— Part D claims (CY24) · First FDA approval: 2024-05-01

Brand-only (no generics)

Low NADAC$0.170

→

Avg plan cost$0.177

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Pioglitazone and Glimepiride

Brand: Duetact · — Part D claims (CY24) · First FDA approval: 2006-07-28

1 generic mfrs 0 plans require PA

Low NADAC$10.78

→

Avg plan cost$10.88

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.